Board of Directors
Jim has been a partner of the venture capital firm Domain and Associates since the firm’s founding in 1985. Jim has more than 40 years of experience with venture and emerging growth companies. He has been involved in the creation and successful development at the board level of more than 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Cadence Pharmaceuticals, Dura Pharmaceuticals, GeneOhm Sciences, and Molecular Dynamics.
Alex is a life sciences executive with over 25 years experience leading strategic initiatives that have transformed small companies and enabled large companies to penetrate new markets. Most recently, he was the Senior Vice President of Strategic Initiatives at Illumina, Inc. where his responsibilities included working with national governments and large institutions to develop precision medicine programs for healthcare systems.
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields. He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer’s disease.
Carol Gallagher is a Partner at NEA, joining in October, 2014. Carol is a proven entrepreneur, operator and more recently investor with nearly 30 years of experience in commercial, drug development and business development roles. Prior to joining NEA she was a Venture Partner with Frazier Healthcare and she served as an independent director on multiple Boards. From 2008-2011, Carol was president and CEO of Calistoga Pharmaceuticals which developed the first-in-class therapeutic now marketed by Gilead as ZYDELIG. Prior to Calistoga she served in various leadership roles at both large pharma and small biotech.
In addition to serving as a director at Chromacode, she serves as Chairman of the Board at Millendo Therapeutics, lead director at Atara Bio, and as a director at Metacrine, PIONYR Immunotherapeutics, XOC, and Qpex.
Aditya is the inventor of HDPCR, ChromaCode’s core technology. Previously, he was a researcher at Google[x], where he worked on novel medical imaging methods. He has expertise in thermal engineering, digital signal processing, nano-scale electronics, low-power circuit design for implantable sensors, DNA sequencing structures and techniques, and PCR devices and applications.
Yaser is a Professor of Electrical Engineering and Computer Science at the California Institute of Technology, and Chairman of Machine Learning Consultants LLC. His main fields of expertise are machine learning and computational finance. He is the author of Amazon’s machine learning bestseller Learning from Data. His MOOC on machine learning has attracted more than two million views.
Andrea is the Chair of the Division of Molecular Diagnostics in the Department of Pathology at the Virginia Commonwealth University Health System. She is also the director of the Molecular Diagnostics Laboratory at the VCU Health System.
Michael has been an Engineering Director at Google since 2002 where his responsibilities have ranged from managing large engineering teams responsible for most of Google’s revenue, to overseeing critical internal software infrastructure projects. Michael currently leads a Google Research team that he founded, whose primary aim is to bring Google’s expertise in machine intelligence and machine perception to bear on fundamental scientific research.
Dr. David Hillyard is Director of Molecular Infectious Disease Testing at ARUP Laboratories, a leading institution for esoteric laboratory testing, and a Professor of Pathology at the University of Utah. Dr. Hillyard is a renowned expert in infectious disease test development and utilization and has authored over 100 papers in the field. In 2014 he was inducted into the National Academy of Inventors. He currently serves as the Chair of the Infectious Disease Subdivision for the Association of Molecular Pathology.
Greg is the Director of the Laboratory for Clinical Genomics and Advanced Technology (CGAT) at the Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center in Lebanon, NH and a Professor of Pathology at the Geisel School of Medicine at Dartmouth in Hanover, NH. He was the inaugural director of the molecular pathology laboratory at Hartford Hospital in Hartford, CT before going to Dartmouth.